Pegcetacoplan Global Patent Coverage & Expiry Overview

Track protection status across key markets to assess launch feasibility.

Start your free 7-Day Trial! Book a demo to explore our global patent data.

It is formulated by 1 pharmaceutical company such as APELLIS PHARMS. It is marketed under 2 brand names, including EMPAVELI, SYFOVRE. Available in 2 different strengths, such as 1080MG/20ML (54MG/ML), 15MG/0.1ML (15MG/0.1ML), and administered through 2 routes including SOLUTION;SUBCUTANEOUS, SOLUTION;INTRAVITREAL.

Strategic Dashboard

info

insightsStrategic Insights

Sourcing & Feasibility

check_circle API availability: autorenew Loading API feasibility...

groups Licensing: 1 potential partners

calendar_todayUS Launch window: autorenew Loading launch window...

timeline Key Patent Barrier & Expiry Timeline

autorenew Loading patent barriers...

factoryGeneric Manufacturer Snapshot

autorenew Loading manufacturers...

gavelRisk & Opportunity Summary

dangerous Risk: autorenew Loading risk analysis...
watch_later Watch: autorenew Loading watch analysis...
rocket_launch Opportunity: autorenew Loading opportunity analysis...
flag
gavel
calendar_today
calendar_today

Access Global Patent Data

Stay ahead with worldwide patent expiry and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patents

Orange Book Drug Approval Timeline

FDA approval history for this ingredient

NDA (New Drug Application) ANDA (Generic Application)

Access Global Exclusivity and Patent Expiry Extensions

Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
✓ Latest exclusivity data and extensions
Unlock Global Access

US Orange Book Patents Expiration Timeline

Key expiration dates for US patents covering this ingredient

View Global Patents Expiration Timeline

Stay ahead with worldwide patent expiry insights, market data, and research updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patent Timeline

Orange Book Drug Strengths

Latest drug strengths approved by FDA

Strength Route of Administration Companies Latest Approval Date

Orange Book Patents

Patents approved by the FDA for the ingredient

Patent Number Publication Date Legal Status Patent Expiry Date
{"application_id":"111825","ingredient":"PEGCETACOPLAN","trade_name":"SYFOVRE","family_id":"1a95e022af524dbdafd1","publication_number":"US9056076B2","cleaned_patent_number":"9056076","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2026-10-25","publication_date":"2015-06-16","legal_status":"Granted"} US9056076B2 16 Jun, 2015 Granted 25 Oct, 2026
{"application_id":"111796","ingredient":"PEGCETACOPLAN","trade_name":"SYFOVRE","family_id":"1a95e022af524dbdafd1","publication_number":"US8168584B2","cleaned_patent_number":"8168584","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-04-07","publication_date":"2012-05-01","legal_status":"Granted"} US8168584B2 01 May, 2012 Granted 07 Apr, 2027
{"application_id":"77423","ingredient":"PEGCETACOPLAN","trade_name":"EMPAVELI","family_id":"5d01c84b4093493cb428","publication_number":"US9169307B2","cleaned_patent_number":"9169307","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-11-18","publication_date":"2015-10-27","legal_status":"Granted"} US9169307B2 Molecular 27 Oct, 2015 Granted 18 Nov, 2027
{"application_id":"77452","ingredient":"PEGCETACOPLAN","trade_name":"EMPAVELI","family_id":"5d01c84b4093493cb428","publication_number":"US7888323B2","cleaned_patent_number":"7888323","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-12-04","publication_date":"2011-02-15","legal_status":"Granted"} US7888323B2 Molecular 15 Feb, 2011 Granted 04 Dec, 2027
{"application_id":"77459","ingredient":"PEGCETACOPLAN","trade_name":"EMPAVELI","family_id":"3f34ba95e90f4f40be3e","publication_number":"US7989589B2","cleaned_patent_number":"7989589","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-12-04","publication_date":"2011-08-02","legal_status":"Granted"} US7989589B2 Molecular 02 Aug, 2011 Granted 04 Dec, 2027
{"application_id":"77507","ingredient":"PEGCETACOPLAN","trade_name":"EMPAVELI","family_id":"826d0741e93747bb9aef","publication_number":"US11661441B2","cleaned_patent_number":"11661441","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-01-13","publication_date":"2023-05-30","legal_status":"Granted"} US11661441B2 Molecular 30 May, 2023 Granted 13 Jan, 2033
{"application_id":"77483","ingredient":"PEGCETACOPLAN","trade_name":"EMPAVELI","family_id":"2c06af626819421cb32b","publication_number":"US10125171B2","cleaned_patent_number":"10125171","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-08-02","publication_date":"2018-11-13","legal_status":"Granted"} US10125171B2 Molecular 13 Nov, 2018 Granted 02 Aug, 2033
{"application_id":"77411","ingredient":"PEGCETACOPLAN","trade_name":"EMPAVELI","family_id":"37ba26ead11442f692b9","publication_number":"US10035822B2","cleaned_patent_number":"10035822","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-11-15","publication_date":"2018-07-31","legal_status":"Granted"} US10035822B2 Molecular 31 Jul, 2018 Granted 15 Nov, 2033
{"application_id":"77374","ingredient":"PEGCETACOPLAN","trade_name":"EMPAVELI","family_id":"37ba26ead11442f692b9","publication_number":"US10875893B2","cleaned_patent_number":"10875893","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-11-15","publication_date":"2020-12-29","legal_status":"Granted"} US10875893B2 Molecular 29 Dec, 2020 Granted 15 Nov, 2033
{"application_id":"77412","ingredient":"PEGCETACOPLAN","trade_name":"EMPAVELI","family_id":"37ba26ead11442f692b9","publication_number":"US11292815B2","cleaned_patent_number":"11292815","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-11-15","publication_date":"2022-04-05","legal_status":"Granted"} US11292815B2 Molecular Formulation 05 Apr, 2022 Granted 15 Nov, 2033
{"application_id":"122903","ingredient":"PEGCETACOPLAN","trade_name":"SYFOVRE","family_id":"","publication_number":"US11903994B2","cleaned_patent_number":"11903994","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2037-02-22","publication_date":"2024-02-20","legal_status":"Granted"} US11903994B2 20 Feb, 2024 Granted 22 Feb, 2037
{"application_id":"77358","ingredient":"PEGCETACOPLAN","trade_name":"EMPAVELI","family_id":"ce73454ca4b040b8a218","publication_number":"US11040107B2","cleaned_patent_number":"11040107","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2038-04-09","publication_date":"2021-06-22","legal_status":"Granted"} US11040107B2 Formulation 22 Jun, 2021 Granted 09 Apr, 2038
{"application_id":"77369","ingredient":"PEGCETACOPLAN","trade_name":"EMPAVELI","family_id":"ce73454ca4b040b8a218","publication_number":"US11844841B2","cleaned_patent_number":"11844841","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2038-12-09","publication_date":"2023-12-19","legal_status":"Granted"} US11844841B2 Formulation 19 Dec, 2023 Granted 09 Dec, 2038
{"application_id":"164440","ingredient":"PEGCETACOPLAN","trade_name":"EMPAVELI","family_id":"","publication_number":"US12290566B2","cleaned_patent_number":"12290566","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2038-12-14","publication_date":"2025-05-06","legal_status":"Granted"} US12290566B2 Formulation 06 May, 2025 Granted 14 Dec, 2038

Recent Clinical Trials

Latest clinical trials and research studies for this ingredient

NCT ID Title Status Phase Conditions Start Date Completion Date

API Suppliers/Manufacturer (Branded/Generic companies)

Manufacturing Locations

View Complete Supplier List

Unlock access to all suppliers of Pegcetacoplan

✓ Access a comprehensive list of global suppliers
✓ Get information on each supplier
Unlock Suppliers

Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.

GreyB © 2025 Elixir. All rights reserved.